Aquatic Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Aquatic Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-11,807	Closed	-$639K	–	1421
2025 Q3	$639K	Buy	+11,807	New	+$675K	0.01%	807
2024 Q4	–	Sell	-198,000	Closed	-$13.9M	–	1345
2024 Q3	$13.9M	Buy	+198,000	New	+$16.6M	0.36%	77
2024 Q2	–	Sell	-16,000	Closed	-$1.4M	–	1247
2024 Q1	$1.4M	Sell	16,000 -26,500	-62%	-$2.37M	0.05%	326
2023 Q4	$4.1M	Buy	+42,500	New	+$3.76M	0.1%	197
2023 Q3	–	Sell	-6,100	Closed	-$529K	–	1264
2023 Q2	$529K	Sell	6,100 -32,100	-84%	-$3.02M	0.03%	438
2023 Q1	$3.71M	Buy	+38,200	New	+$3.96M	0.23%	116
2022 Q4	–	Sell	-21,600	Closed	-$1.83M	–	1378
2022 Q3	$1.83M	Buy	+21,600	New	+$1.92M	0.18%	161
2022 Q2	–	Sell	-700	Closed	-$54K	–	1213
2022 Q1	$54K	Buy	+700	New	+$58.6K	0.08%	268

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Aquatic Capital Management's BMRN Position: Q4 2025 in Review

Aquatic Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 11,807 shares — an estimated $639K sold.

Aquatic Capital Management first reported a position in BMRN in Q1 2022 and held it in 8 quarters. The position peaked at $13.9M in Q3 2024. 538 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

Aquatic Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Aquatic Capital Management sold 11,807 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $639K.
Aquatic Capital Management first reported a position in BioMarin Pharmaceuticals in Q1 2022 and held it in 8 quarters.
Aquatic Capital Management's BioMarin Pharmaceuticals position peaked at $13.9M in Q3 2024.
538 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on Aquatic Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.